BioAtla, Inc. (BCAB)

3.2500 +0.0900 (+2.85%) At close: 04:00PM EDT

BioAtla, Inc.

11085 Torreyana Road
San Diego, CA 92121
United States
858 558 0708
https://www.bioatla.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jay M. Short Ph.D.	Co-Founder, CEO & Chairman	1.13M	N/A	1958
Mr. Richard A. Waldron	Senior VP & CFO	655.94k	N/A	1954
Dr. Eric L. Sievers M.D.	Chief Medical Officer	654.59k	N/A	1964
Mr. Christian J. Vasquez	Chief Accounting Officer, Controller and Corporate Secretary	408.75k	N/A	1976
Ms. Susie Melody	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Cathy Chang Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Dr. Gerhard Frey Ph.D.	Senior Vice President of Technology Development	N/A	N/A	N/A
Ms. Monica Sullivan	Senior Vice President of Intellectual Property & Contracts	N/A	N/A	N/A
Ms. Sheri Lydick	Chief Commercial Officer	N/A	N/A	N/A
Dr. Bin Zhang	Senior Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Corporate governance

BioAtla, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.